Top

Wen Jiang, MD, PhD

Department of CNS - Rad Onc Clinical, Division of Radiation Oncology

About Dr. Wen Jiang

Dr. Jiang is currently an Associate Professor with tenure in the Department of Radiation Oncology and a Physician-Scientist in the CNS section. Dr. Jiang received his PhD in Bioengineering from the University of Toronto and his MD from Stanford University. He completed his residency training at MD Anderson Cancer Center in 2018. He subsequently joined UT Southwestern Medical Center as a tenure-track assistant professor of Radiation Oncology and a CPRIT Scholar prior to returning to MD Anderson in 2021. Dr. Jiang cares for patients with primary and secondary CNS tumors. His research focuses on the understanding of immune suppressive mechanisms within solid tumors and identifying novel therapeutic strategies to overcome immune escape. Dr. Jiang’s research is supported by CPRIT, NCI, NINDS, the Department of Defense, the American Cancer Society, and the Susan G. Komen Foundation.

Primary Appointment

Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2013	Stanford University, Stanford, California, US, MD
2008	University of Toronto, Toronto, CA, Biomedical Engineering, Ph.D
2003	Carleton University, Ottawa, CA, Electrical Engineering, BS

Postgraduate Training

2014-2018	Clinical Residency, Radiation Oncology, MD Anderson Cancer Center, Houston, Texas
2013-2014	Clinical Internship, Internal Medicine, Santa Clara Valley Medical Center, San Jose, California
2009-2013	Research Fellowship, Tumor Immunology, Stanford School of Medicine, Stanford, California
2008-2009	Research Fellowship, Tumor Biology, Massachusetts General Hospital, Boston, Massachusetts

Board Certifications

2019	American Board of Radiology

Experience & Service

Academic Appointments

Assistant Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2023

Assistant Professor, Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, 2018 - 2021

Other Appointments/Responsibilities

Consultant, Innovent, Houston, TX, 2021 - Present

Institutional Committee Activities

Member, Faculty Recruitment Committee, 2024 - Present

Member, Odyssey Fellowship Committee, 2024 - Present

Member, Breakthrough Cancer GBM Team, 2022 - Present

Member, Brain Tumor Center Executive Committee, 2021 - Present

Member, Radiation Oncology Strategic Initiative (ROSI) ImmunoRT Committee, 2021 - Present

Honors & Awards

2025 - Present	Elected Member, American Society for Clinical Investigation
2024	Andrew Sabin Family Foundation Fellowship, UT-MD Anderson Cancer Center
2024	Willie Tichenor Fellowship in Sarcoma Research, UT-MD Anderson Cancer Center
2023	Faculty Research Excellence Award, UT MD Anderson Cancer Center
2023	Faculty Scholar Award, UT MD Anderson Cancer Center
2019	NCI K08 Mentored Clinician-Scientist Career Development Award, NCI
2019	Circle of Friends Cancer Research Award, UT Southwestern
2018	A. Lavoy Moore Endowed Clinical Fellow, MD Anderson
2018	CPRIT Scholar in Cancer Research, CPRIT
2018	Jeffrey Lee Cousins Fellowship in Lung Cancer Research, MD Anderson
2018	Rising STARS Award, University of Texas System
2017	ASCO Young Investigator Award, Conquer Cancer Foundation
2017	Annual Meeting Travel Award, ASTRO
2017	Roentgen Resident/Fellow Research Award, RSNA
2017	Susan Papizan Dolan Fellowship in Breast Oncology, MD Anderson
2016	Research Resident Grant, RSNA Annual Meeting
2016	Trainee Award - E.D. Montague Research Excellence Award, MD Anderson
2016	Travel Award, RSNA Annual Meeting
2016	Workshop on Methods in Clinical Cancer Research, AACR/ASCO - Vail, CO
2015	Trainee Award – Gilbert Fletcher Society Award, MD Anderson
2014	Young Alumni Achievement Award, Carleton University
2011	Banting Postdoctoral Fellowship Award, Government of Canada
2010	Scholar Research Fellowship, Stanford Medical
2008	1st Place: School of Graduate Studies, University of Toronto
2008	Brain Star National Award, Canadian Institutes of Health Research (CIHR)
2008	Distinguished Graduate Student Dissertation Award, University of Toronto
2008	Graduate Student Award, National Cancer Institute of Canada (NCIC)
2008	John Leyerle-Canadian Institute for Advanced Research (CIFAR) Award, Canadian Institute for Advanced Research (CIFAR)
2008	Paul B. Madsen Award, University of Toronto
2008	Post-Doctoral Fellowship, Natural Science and Engineering Research Council of Canada
2005	Alexander Graham Bell Canada Scholarship for Doctoral Studies, NSERC
2003	Ontario Graduate Scholarship for Academic Excellence, Ontario
2003	Senate Medal for Outstanding Academic Achievement, Carleton University
2002	Chipworks Award for Excellence in Electrical Engineering, Carleton University
1999 - 2003	Dean’s Honor List, Carleton University
1999	Nortel Networks Scholarship, Nortel Networks
1999	Ontario Scholar, Ontario
1999	Ottawa Hydro Top Electrical Engineer Scholarship, Ottawa

Professional Memberships

ASTRO Research Grants Evaluation Subcommittee

2020 - Present

ASTRO Science Education and Program Development Subcommittee

2020 - Present

American Society of Clinical Oncology (ASCO)

2019 - Present

Society for Immunotherapy of Caner (SITC)

2019 - Present

Society for Neuro-Oncology (SNO)

2018 - Present

American Brain Tumor Association Alumni Research Network (AARN)

2015 - Present

American Society for Radiology and Oncology (ASTRO)

2014 - Present

Radiological Society of North America (RSNA)

2014 - 2018

American Association for Cancer Research (AACR)

2014 - Present

American Chemical Society

2004 - 2009

Biomedical Engineering Society (BMES)

2004 - 2005

Selected Publications

Peer-Reviewed Articles

Tang K, Tang Z, Niu M, Kuang Z, Xue W, Wang X, Liu X, Yu Y, Jeong S, Ma Y, Wu A, Kim BYS, Jiang W, Yang Z, Li C. Allosteric targeted drug delivery for enhanced blood-brain barrier penetration via mimicking transmembrane domain interactions. Nat Commun 16(1):3410, 2025. e-Pub 2025. PMID: 40210849.
Khorsandi S, Huntoon K, Wang Y, Woodward A, Antony A, Endsley C, Hafeez N, Edwards JL, McCuen N, Alluri PG, Kim BYS, Jiang W, Lux J. Targeted STING Activation Using Modified Ultrasound-Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma. Adv Sci (Weinh):e2416596, 2025. e-Pub 2025. PMID: 40135812.
Schrank, BR, Wang, Y, Wu, A, Tran, N, Lee, DY, Edwards, J, Huntoon, K, Dong, S, Ha, JH, Ma, Y, Grippin, A, Jeong, S, Antony, A, Chang, M, Kang, M, Gallup, T, Koong, A, Li, J, Yun, K, Kim, BY, Jiang, W. An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nature Cancer 6(3):511-527, 2025. e-Pub 2025. PMID: 40000910.
Schrank BR, Jiang W. An antibody-toxin conjugate enhances innate immune cell responses in tumors. Nat Cancer 6(3):415-416, 2025. e-Pub 2025. PMID: 40038505.
Gao F, Liu X, Ma Z, Tang M, Tang Z, Wu J, Luo M, Tang Y, Wang X, Wang B, Kim BYS, Yang Z, Jiang W, Tang P, Li C. An Integrated Modular Vaccination System for Spatiotemporally Separated Perioperative Cancer Immunotherapy. Adv Mater 37(11):e2418322, 2025. e-Pub 2025. PMID: 39924759.
You Y, Tian Y, Guo R, Shi J, Kwak KJ, Tong Y, Estania AP, Hsu WH, Liu Y, Hu S, Cao J, Yang L, Bai R, Huang P, Lee LJ, Jiang W, Kim BYS, Ma S, Liu X, Shen Z, Lan F, Phuong Nguyen PK, Lee AS. Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity. Eur Heart J, 2025. e-Pub 2025. PMID: 39831819.
Wang Y, Schrank BR, Jiang W, Kim BYS. Learning what keeps nanomedicines in tumours. Nat Biomed Eng 8(11):1330-1331, 2024. e-Pub 2024. PMID: 39271934.
Beckham TH, Rooney MK, McAleer MF, Ghia AJ, Tom MC, Perni S, McGovern S, Grosshans D, Chung C, Wang C, De B, Swanson T, Paulino A, Jiang W, Ferguson S, Patel CB, Li J, Yeboa DN. Hypofractionated radiotherapy for glioblastoma: A large institutional retrospective assessment of 2 approaches. Neurooncol Pract 11(3):266-274, 2024. e-Pub 2024. PMID: 38737610.
Lee D, Huntoon K, Wang Y, Kang M, Lu Y, Jeong SD, Link TM, Gallup TD, Qie Y, Li X, Dong S, Schrank BR, Grippin AJ, Antony A, Ha J, Chang M, An Y, Wang L, Jiang D, Li J, Koong AC, Tainer JA, Jiang W, Kim BYS. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nat Biomed Eng 8(5):593-610, 2024. e-Pub 2024. PMID: 38641710.
Bian X, Yang L, Jiang D, Grippin AJ, Ma Y, Wu S, Wu L, Wang X, Tang Z, Tang K, Pan W, Dong S, Kim BYS, Jiang W, Yang Z, Li C. Regulation of cerebral blood flow boosts precise brain targeting of vinpocetine-derived ionizable-lipidoid nanoparticles. Nat Commun 15(1):3987, 2024. e-Pub 2024. PMID: 38734698.
Sun L, Niu H, Wu Y, Dong S, Li X, Kim BYS, Liu C, Ma Y, Jiang W, Yuan Y. Bio-integrated scaffold facilitates large bone regeneration dominated by endochondral ossification. Bioact Mater 35:208-227, 2024. e-Pub 2024. PMID: 38327823.
Chang M, Wang M, Liu B, Zhong W, Jana D, Wang Y, Dong S, Antony A, Li C, Liu Y, Zhao Z, Lin J, Jiang W, Zhao Y. A Cancer Nanovaccine Based on an FeAl-Layered Double Hydroxide Framework for Reactive Oxygen Species-Augmented Metalloimmunotherapy. ACS Nano 18(11):8143-8156, 2024. e-Pub 2024. PMID: 38436248.
Li X, Huntoon K, Wang Y, Lee D, Dong S, Antony A, Walkey C, Kim BYS, Jiang W. Radiation Synergizes with IL-2/IL-15 Stimulation to Enhance Innate Immune Activation and Antitumor Immunity. Mol Cancer Ther 23(3):330-342, 2024. e-Pub 2024. PMID: 37956421.
Wang Y, Deng W, Lee D, Yan L, Lu Y, Dong S, Huntoon K, Antony A, Li X, Ye R, Zhao Y, Zhao F, Schrank BR, Ha J, Kang M, Yang M, Gong P, Lorenzi PL, Tan L, Gallup TD, Tang SK, Yang Z, Li J, Sanford NN, Wang H, Kim BYS, Jiang W. Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics. Nat Nanotechnol 19(2):255-263, 2024. e-Pub 2024. PMID: 37723279.
Zhang J, Rima XY, Wang X, Nguyen LTH, Huntoon K, Ma Y, Palacio PL, Nguyen KT, Albert K, Duong-Thi MD, Walters N, Kwak KJ, Yoon MJ, Li H, Doon-Ralls J, Hisey CL, Lee D, Wang Y, Ha J, Scherler K, Fallen S, Lee I, Palmer AF, Jiang W, Magaña SM, Wang K, Kim BYS, Lee LJ, Reátegui E. Engineering a tunable micropattern-array assay to sort single extracellular vesicles and particles to detect RNA and protein in situ. J Extracell Vesicles 12(11):e12369, 2023. e-Pub 2023. PMID: 37908159.
Chiang CL, Ma Y, Hou YC, Pan J, Chen SY, Chien MH, Zhang ZX, Hsu WH, Wang X, Zhang J, Li H, Sun L, Fallen S, Lee I, Chen XY, Chu YS, Zhang C, Cheng TS, Jiang W, Kim BYS, Reategui E, Lee R, Yuan Y, Liu HC, Wang K, Hsiao M, Huang CF, Shan YS, Lee AS, James Lee L. Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer. Nat Commun 14(1):6692, 2023. e-Pub 2023. PMID: 37872156.
Dong S, Liu X, Bi Y, Wang Y, Antony A, Lee D, Huntoon K, Jeong S, Ma Y, Li X, Deng W, Schrank BR, Grippin AJ, Ha J, Kang M, Chang M, Zhao Y, Sun R, Sun X, Yang J, Chen J, Tang SK, Lee LJ, Lee AS, Teng L, Wang S, Teng L, Kim BYS, Yang Z, Jiang W. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nat Commun 14(1):6610, 2023. e-Pub 2023. PMID: 37857647.
You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Tong Y, Estania AP, Cao J, Hsu WH, Liu Y, Chiang CL, Schrank BR, Huntoon K, Lee D, Li Z, Zhao Y, Zhang H, Gallup TD, Ha J, Dong S, Li X, Wang Y, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F, Kim BYS, Lee AS. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nat Biomed Eng 7(7):887-900, 2023. e-Pub 2023. PMID: 36635419.
Huntoon K, Anderson SK, Ballman KV, Twohy E, Dooley K, Jiang W, An Y, Li J, von Roemeling C, Qie Y, Ross OA, Cerhan JH, Whitton AC, Greenspoon JN, Parney IF, Ashman JB, Bahary JP, Hadjipanayis C, Urbanic JJ, Farace E, Khuntia D, Laack NN, Brown PD, Roberge D, Kim BYS. Association of Circulating Markers with Cognitive Decline After Radiation Therapy for Brain Metastasis. Neuro Oncol 25(6):1123-1131, 2023. e-Pub 2023. PMID: 36472389.
Lu Y, Huntoon K, Lee D, Wang Y, Ha J, Qie Y, Li X, Schrank BR, Dong S, Gallup TD, Kang M, Zhao H, An Y, Yang Z, Li J, Kim BYS, Jiang W. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nat Nanotechnol 17(12):1332-1341, 2022. e-Pub 2022. PMID: 36357792.
Huang X, Liu Q, Zhong G, Peng Y, Liu Y, Liang L, Hong H, Feng W, Yang S, Zhang Y, Xian S, Li Z, Zhou Y, Zhang Z, Jiang W, Liang J, Liu ZG. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial. J Exp Clin Cancer Res 41(1):300, 2022. e-Pub 2022. PMID: 36224603.
Li X, Khorsandi S, Wang Y, Santelli J, Huntoon K, Nguyen N, Yang M, Lee D, Lu Y, Gao R, Kim BYS, de Gracia Lux C, Mattrey RF, Jiang W, Lux J. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Nat Nanotechnol 17(8):891-899, 2022. e-Pub 2022. PMID: 35637356.
Li J, Xue C, Wang H, Dong S, Yang Z, Cao Y, Zhao B, Cheng B, Xie X, Mo X, Jiang W, Yuan H, Pan J. Hybrid Nanofibrous Composites with Anisotropic Mechanics and Architecture for Tendon/Ligament Repair and Regeneration. Small 18(27):e2201147, 2022. e-Pub 2022. PMID: 35686342.
George J, Chen Y, Abdelfattah N, Yamamoto K, Gallup TD, Adamson SI, Rybinski B, Srivastava A, Kumar P, Lee MG, Baskin DS, Jiang W, Choi JM, Flavahan W, Chuang JH, Kim BYS, Xu J, Jung SY, Yun K. Cancer stem cells, not bulk tumor cells, determine mechanisms of resistance to SMO inhibitors. Cancer Research Communications 2(6):402-416, 2022. e-Pub 2022.
Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, Liu Q, Su S, Zeng Y, Jia W, Yang Y, Xu S, Yao H, Jiang W, Song E. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun 13(1):3011, 2022. e-Pub 2022. PMID: 35641481.
Hein DM, Deng W, Bleile M, Kazmi SA, Rhead B, De La Vega FM, Jones AL, Kainthla R, Jiang W, Cantarel B, Sanford NN. Racial and Ethnic Differences in Genomic Profiling of Early-Onset Colorectal Cancer. J Natl Cancer Inst 114(5):775-778, 2022. e-Pub 2022. PMID: 35134211.
Dong S, Bi Y, Sun X, Zhao Y, Sun R, Hao F, Sun Y, Wang Y, Li X, Deng W, Liu X, Ha J, Teng L, Gong P, Xie J, Kim BYS, Yang Z, Jiang W, Teng L. Dual-Loaded Liposomes Tagged with Hyaluronic Acid Have Synergistic Effects in Triple-Negative Breast Cancer. Small 18(16):e2107690, 2022. e-Pub 2022. PMID: 35277914.
Abdelfattah N, Kumar P, Wang C, Leu JS, Flynn WF, Gao R, Baskin DS, Pichumani K, Ijare OB, Wood SL, Powell SZ, Haviland DL, Parker Kerrigan BC, Lang FF, Prabhu SS, Huntoon KM, Jiang W, Kim BYS, George J, Yun K. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun 13(1):767, 2022. e-Pub 2022. PMID: 35140215.
Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, Charbonneau CM, Sugarman E, Bowie M, Hariharan S, Waitkus M, Jiang W, McLendon RE, Pan E, Khasraw M, Walsh KM, Lu Y, Herlyn M, Mills G, Herbig U, Wei Z, Keir ST, Flaherty K, Liu L, Wu K, Shay JW, Abdullah K, Zhang G, Ashley DM. A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas. Clin Cancer Res 27(24):6800-6814, 2021. e-Pub 2021. PMID: 34593527.
Sun Z, Deng G, Peng X, Xu X, Liu L, Peng J, Ma Y, Zhang P, Wen A, Wang Y, Yang Z, Gong P, Jiang W, Cai L. Intelligent photothermal dendritic cells restart the cancer immunity cycle through enhanced immunogenic cell death. Biomaterials 279:121228, 2021. e-Pub 2021. PMID: 34717198.
Liu Y, Yang Z, Wang L, Sun L, Kim BYS, Jiang W, Yuan Y, Liu C. Spatiotemporal Immunomodulation Using Biomimetic Scaffold Promotes Endochondral Ossification-Mediated Bone Healing. Adv Sci (Weinh) 8(11):e2100143, 2021. e-Pub 2021. PMID: 34105266.
Ma Y, Yang Z, Huntoon K, Jiang W, Kim BYS. Advanced immunotherapy approaches for glioblastoma. Advanced Therapeutics 4(8), 2021. e-Pub 2021.
Zhang N, Yin R, Zhou P, Liu X, Fan P, Qian L, Dong L, Zhang C, Zheng X, Deng S, Kuai J, Liu Z, Jiang W, Wang X, Wu D, Huang Y. DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression. Proc Natl Acad Sci U S A 118(22), 2021. e-Pub 2021. PMID: 34035167.
Sun X, Yu K, Zhou Y, Dong S, Hu W, Sun Y, Li Y, Xie J, Lee RJ, Sun F, Ma Y, Wang S, Kim BYS, Wang Y, Yang Z, Jiang W, Li Y, Teng L. Self-Assembled pH-Sensitive Polymeric Nanoparticles for the Inflammation-Targeted Delivery of Cu/Zn-Superoxide Dismutase. ACS Appl Mater Interfaces 13(15):18152-18164, 2021. e-Pub 2021. PMID: 33764751.
Huang C, Chen L, Savage SR, Eguez RV, Dou Y, Li Y, da Veiga Leprevost F, Jaehnig EJ, Lei JT, Wen B, Schnaubelt M, Krug K, Song X, Cieslik M, Chang HY, Wyczalkowski MA, Li K, Colaprico A, Li QK, Clark DJ, Hu Y, Cao L, Pan J, Wang Y, Cho KC, Shi Z, Liao Y, Jiang W, Anurag M, Ji J, Yoo S, Zhou DC, Liang WW, Wendl M, Vats P, Carr SA, Mani DR, Zhang Z, Qian J, Chen XS, Pico AR, Wang P, Chinnaiyan AM, Ketchum KA, Kinsinger CR, Robles AI, An E, Hiltke T, Mesri M, Thiagarajan M, Weaver AM, Sikora AG, Lubinski J, Wierzbicka M, Wiznerowicz M, Satpathy S, Gillette MA, Miles G, Ellis MJ, Omenn GS, Rodriguez H, Boja ES, Dhanasekaran SM, Ding L, Nesvizhskii AI, El-Naggar AK, Chan DW, Zhang H, Zhang B, Analysis Consortium CPT. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell 39(3):361-379.e16, 2021. e-Pub 2021. PMID: 33417831.
Xie S, Shalaby-Rana E, Hester A, Honeycutt J, Fu CL, Boyett D, Jiang W, Hsieh MH. Macroscopic and microscopic imaging modalities for diagnosis and monitoring of urogenital schistosomiasis. Adv Parasitol 112:51-76, 2021. e-Pub 2021. PMID: 34024359.
Westover KD, Mendel JT, Dan T, Kumar K, Gao A, Pulipparacharuv S, Iyengar P, Nedzi L, Hannan R, Anderson J, Choe KS, Jiang W, Abdulrahman R, Rahimi A, Folkert M, Laine A, Presley C, Cullum CM, Choy H, Ahn C, Timmerman R. Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. Neuro Oncol 22(12):1831-1839, 2020. e-Pub 2020. PMID: 32347302.
Deng W, Wang Y, Liu X, Liu J, Wang L, Yang Z, Yang M, An Y, Tang C, Sanford NN, Kim BYS, Jiang W. Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. JAMA Netw Open 3(12):e2028627, 2020. e-Pub 2020. PMID: 33295975.
Wei W, Jiang H, Chen W, Zhou Y, Guo S, Zhong G, Zhou H, Wang S, Zhang H, Jiang W, Liu ZG. How should we implement radiotherapy for cancer patients in China during the endemic period of COVID-19?. Radiother Oncol 147:100-102, 2020. e-Pub 2020. PMID: 32259751.
Wang L, Dong S, Liu Y, Ma Y, Zhang J, Yang Z, Jiang W, Yuan Y. Fabrication of Injectable, Porous Hyaluronic Acid Hydrogel Based on an In-Situ Bubble-Forming Hydrogel Entrapment Process. Polymers (Basel) 12(5), 2020. e-Pub 2020. PMID: 32429363.
Li Q, Wang Y, Jia W, Deng H, Li G, Deng W, Chen J, Kim BYS, Jiang W, Liu Q, Liu J. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clin Cancer Res 26(7):1712-1724, 2020. e-Pub 2020. PMID: 31848190.
Wei W, Zhou J, Zhang Q, Liao DH, Liu QD, Zhong BL, Liang ZB, Zhang YC, Jiang R, Liu GY, Xu CY, Li Zhou H, Zhu SY, Yang N, Jiang W, Liu ZG. Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study. Cancer Med 9(8):2820-2832, 2020. e-Pub 2020. PMID: 32100444.
Zheng X, Zhang N, Qian L, Wang X, Fan P, Kuai J, Lin S, Liu C, Jiang W, Qin S, Chen H, Huang Y. CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils. Int J Cancer 146(6):1730-1740, 2020. e-Pub 2020. PMID: 31840816.
von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, Yang Z, Yang M, Deng W, Bruno KA, Chan CK, Lee AS, Rosenfeld SS, Yun K, Johnson AJ, Mitchell DA, Jiang W, Kim BYS. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun 11(1):1508, 2020. e-Pub 2020. PMID: 32198351.
Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, Zhao Y, Zhao X, Wang X, Ma Y, Malkoc V, Chiang C, Deng W, Chen Y, Fu Y, Kwak KJ, Fan Y, Kang C, Yin C, Rhee J, Bertani P, Otero J, Lu W, Yun K, Lee AS, Jiang W, Teng L, Kim BYS, Lee LJ. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng 4(1):69-83, 2020. e-Pub 2020. PMID: 31844155.
Li N, Wang Y, Neri S, Zhen Y, Fong LWR, Qiao Y, Li X, Chen Z, Stephan C, Deng W, Ye R, Jiang W, Zhang S, Yu Y, Hung MC, Chen J, Lin SH. Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. Nat Commun 10(1):4363, 2019. e-Pub 2019. PMID: 31554794.
Liu Y, Song Y, Lin D, Lei L, Mei Y, Jin Z, Gong H, Zhu Y, Hu B, Zhang Y, Zhao L, Teo HY, Qiu J, Jiang W, Dong C, Wu D, Huang Y, Liu H. NCR- group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development. EBioMedicine 41:333-344, 2019. e-Pub 2019. PMID: 30827928.
Chen Y, Liu X, Yuan H, Yang Z, von Roemeling CA, Qie Y, Zhao H, Wang Y, Jiang W, Kim BYS. Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery. Adv Sci (Weinh) 6(5):1802070, 2019. e-Pub 2019. PMID: 30886813.
An Y, Jiang W, Andraos TY, Reddy JP, Yehia ZA, Lloyd S, Duvic M, D'Souza NM, Milgrom SA, Pinnix CC, Oki Y, Smith GL, Wilson LD, Dabaja BS. Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol 131:88-92, 2019. e-Pub 2019. PMID: 30773193.
Wang Y, Li N, Jiang W, Deng W, Ye R, Xu C, Qiao Y, Sharma A, Zhang M, Hung MC, Lin SH. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 24(22):5744-5756, 2018. e-Pub 2018. PMID: 30068711.
Zhang Z, Yang J, Ho A, Jiang W, Logan J, Wang X, Brown PD, McGovern SL, Guha-Thakurta N, Ferguson SD, Fave X, Zhang L, Mackin D, Court LE, Li J. A predictive model for distinguishing radiation necrosis from tumour progression after gamma knife radiosurgery based on radiomic features from MR images. Eur Radiol 28(6):2255-2263, 2018. e-Pub 2018. PMID: 29178031.
Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, Han Y, Zhao Y, Lin SH, Qin S, Wang X, Kim BY, Zhou P, Jiang W, Wu Q, Huang Y. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest 128(5):2104-2115, 2018. e-Pub 2018. PMID: 29664018.
Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH. RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. Clin Cancer Res 24(2):341-350, 2018. e-Pub 2018. PMID: 29030353.
Lu J, Liu X, Liao YP, Salazar F, Sun B, Jiang W, Chang CH, Jiang J, Wang X, Wu AM, Meng H, Nel AE. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun 8(1):1811, 2017. e-Pub 2017. PMID: 29180759.
Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys 99(4):812-816, 2017. e-Pub 2017. PMID: 29063850.
Chow KH, Park HJ, George J, Yamamoto K, Gallup AD, Graber JH, Chen Y, Jiang W, Steindler DA, Neilson EG, Kim BYS, Yun K. S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma. Cancer Res 77(19):5360-5373, 2017. e-Pub 2017. PMID: 28807938.
An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80-88, 2017. e-Pub 2017. PMID: 28916225.
Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. Int J Radiat Oncol Biol Phys 98(5):1069-1077, 2017. e-Pub 2017. PMID: 28721890.
Yuan H, Jiang W, von Roemeling CA, Qie Y, Liu X, Chen Y, Wang Y, Wharen RE, Yun K, Bu G, Knutson KL, Kim BYS. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nat Nanotechnol 12(8):763-769, 2017. e-Pub 2017. PMID: 28459470.
Fang P, Jiang W, Allen P, Glitza I, Guha N, Hwu P, Ghia A, Phan J, Mahajan A, Tawbi H, Li J. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neurooncol 133(3):595-602, 2017. e-Pub 2017. PMID: 28500560.
Jiang W, Yuan H, Chan CK, von Roemeling CA, Yan Z, Weissman IL, Kim BYS. Lessons from immuno-oncology: a new era for cancer nanomedicine?. Nat Rev Drug Discov 16(6):369-370, 2017. e-Pub 2017. PMID: 28303024.
Jiang W, von Roemeling C, Qie Y, Chen Y, Liu X, Chen J, Kim BYS. Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering 1:0029, 2017. e-Pub 2017.
Abou Yehia Z, Mikhaeel GN, Smith G, Pinnix CC, Milgrom SA, Tang C, Jiang W, Fanale MA, Oki Y, Shank JH, Horace T, Reddy J, Akhtari M, Gunther JR, Suki T, Allen PK, Turner S, Mawlawi O, Dabaja BS. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. Int J Radiat Oncol Biol Phys 96(5):951-958, 2016. e-Pub 2016. PMID: 27742539.
Jiang W, Liu J, Gullane PJ, Gentili F, Wharen RE, Kim BYS, DeMonte F. Non-contiguous meningeal metastases of olfactory neuroblastoma. J Neurooncol 126(1):201-203, 2016. e-Pub 2016. PMID: 26376653.
Jiang W, Chamberlain PD, Garden AS, Kim BYS, Ma D, Bell D. Prognostic value of p16 expression in Epstein‐Barr virus–positive nasopharyngeal carcinomas. Head & Neck 38, (S1), E1459-E1466, 2016. e-Pub 2016. PMID: 26560893.
Jiang W, Huang Y, An Y, Kim BY. Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano 9(9):8689-96, 2015. e-Pub 2015. PMID: 26212564.
Liu J, Jiang W, Mao K, An Y, Su F, Kim BY, Liu Q, Jacobs LK. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat 150(2):439-45, 2015. e-Pub 2015. PMID: 25764167.
Tang C, Chan C, Jiang W, Murphy JD, von Eyben R, Colevas AD, Pinto H, Lee-Enriquez N, Kong C, Le QT. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head Neck 37(3):386-92, 2015. e-Pub 2015. PMID: 24431011.
Kim BYS, Jiang W, Beiko J, Prabhu SS, DeMonte F, Gilbert MR, Sawaya R, Aldape KD, Cahill DP, McCutcheon IE. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. J Neurooncol 118(2):405-412, 2014. e-Pub 2014. PMID: 24777756.
Tang C, Komakula S, Chan C, Murphy JD, Jiang W, Kong C, Lee-Enriquez N, Jensen KC, Fischbein NJ, Le QT. Radiologic assessment of retropharyngeal node involvement in oropharyngeal carcinomas stratified by HPV status. Radiother Oncol 109(2):293-6, 2013. e-Pub 2013. PMID: 24103114.
Chan CK, Lindau P, Jiang W, Chen JY, Zhang LF, Chen CC, Seita J, Sahoo D, Kim JB, Lee A, Park S, Nag D, Gong Y, Kulkarni S, Luppen CA, Theologis AA, Wan DC, DeBoer A, Seo EY, Vincent-Tompkins JD, Loh K, Walmsley GG, Kraft DL, Wu JC, Longaker MT, Weissman IL. Clonal precursor of bone, cartilage, and hematopoietic niche stromal cells. Proc Natl Acad Sci U S A 110(31):12643-8, 2013. e-Pub 2013. PMID: 23858471.
Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popovic Z, Jain RK, Bawendi MG, Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A 108(6):2426-31, 2011. e-Pub 2011. PMID: 21245339.
Liu W, Greytak AB, Lee J, Wong CR, Park J, Marshall LF, Jiang W, Curtin PN, Ting AY, Nocera DG, Fukumura D, Jain RK, Bawendi MG. Compact biocompatible quantum dots via RAFT-mediated synthesis of imidazole-based random copolymer ligand. J Am Chem Soc 132(2):472-83, 2010. e-Pub 2010. PMID: 20025223.
Kim BY, Jiang W, Oreopoulos J, Yip CM, Rutka JT, Chan WC. Biodegradable quantum dot nanocomposites enable live cell labeling and imaging of cytoplasmic targets. Nano Lett 8(11):3887-92, 2008. e-Pub 2008. PMID: 18816147.
Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3(3):145-50, 2008. e-Pub 2008. PMID: 18654486.
Gryczynski I, Malicka J, Jiang W, Fischer H, Chan WC, Gryczynski Z, Grudzinski W, Lakowicz JR. Surface-plasmon-coupled emission of quantum dots. J Phys Chem B 109(3):1088-93, 2005. e-Pub 2005. PMID: 16851064.

Invited Articles

Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufés C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, Skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, das Neves J, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C. On the issue of transparency and reproducibility in nanomedicine. Nat Nanotechnol 14(7):629-635, 2019. e-Pub 2019. PMID: 31270452.

Editorials

Ha J, Grippin AJ, Kim BYS, Jiang W. Striking the Balance with a PD-L1×4-1BB Bispecific Antibody. Cancer Res 84(10):1546-1547, 2024. PMID: 38745496.
Huntoon K, Jiang W, Kim BY. Waking immune-resistant tumors with neddylation. J Clin Invest 133(4), 2023. PMID: 36787255.
Tang C, Jiang W, Yap TA. Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword. JAMA Oncol 4(8):1116-1117, 2018. PMID: 29327039.
Jiang W. A tale of two disciplines. Nat Nanotechnol 11(8):732, 2016. PMID: 27485586.

Abstracts

Jiang W, Chamberlain PD, Garden AS, Kim BYS, Ma D, Bell D. Prognostic value of p16 expression in Epstein‐Barr virus–positive nasopharyngeal carcinomas. Head & Neck 38, (S1), E1459-E1466, 2016. e-Pub 2016.

Book Chapters

Yoon JW, Jiang W, Huang YH, Rutka JT, Kim BYS. Perspectives of nanotechnology in the management of gliomas. In: Chernov MF, Muragaki Y, Kesari S, McCutcheon IE. Progress in Neurological Surgery. 1st ed. Karger, 2015.
Jiang W, Singhal A, Fischer H, Mardyani S, Chan WCW. Engineering biocompatible quantum dots for real-time, ultrasensitive biological imaging and detection. In: Therapeutic Micro/Nanotechnology, Bhatia S, and Desai T, eds. Kluwer Publishing, 2006.
Mardyani S, Jiang W, Lai J, Zhang J, Chan WCW. Bioinspired approaches to build nanoscale devices. In: Biological Nanostructures and Applications of Nanostructures in Biology, Stoscio M, and Dutta M, eds. Kluwer Publishing, 2004.

Less

Selected Presentations & Talks

Local Presentations

2024. mRNA Delivery Platform. Invited. Investigational Cancer Therapeutics Horizons Meeting. Houston, Texas, US.
2024. Nucleic acids as a new target for treating cancer and other human diseases. Invited. Department of Genetics Research Exchange Seminar Series. Houston, Texas, US.
2023. The Quest for the Next Cancer Therapy Pillar that Complements RT. Invited. Radiation Oncology Grant Rounds. Houston, Texas, US.
2023. Messenger Reloaded: mRNA Therapy for Cancer and Other Human Disease. Invited. Leading Edge of Cancer Research Symposium. Houston, Texas, US.
2023. Bioengineering strategies to cancer immunotherapy. Invited. James P. Allison Institute Seminar Series. Houston, Texas, US.
2023. Intradermally delivered mRNA encapsulating extracellular vesicles for collagen-replacement therapy. Invited. Research Town Hall, US.
2022. Targeting Innate Immune Checkpoints for Cancer Therapy. Invited. Cancer Biology Seminar Serie. Houston, Texas, US.
2022. Engineering approaches to cancer therapy. Invited. Brain Tumor Program Seminar Series. Houston, Texas, US.
2020. Phagocytosis Checkpoints as New Target for Cancer Immunotherapy. Invited. Young Faculty Seminar. Dallas, TX, US.

Regional Presentations

2023. Intradermally delivered mRNA encapsulating extracellular vesicles for collagen-replacement therapy. Conference. MD Anderson Cancer Center, US.
2020. Phagocytosis Checkpoints as New Target for Cancer Immunotherapy. Conference. UTSW Medical Center. Dallas, TX, US.

National Presentations

2025. Engineering approaches to cancer immunotherapy. Invited. Radical Seminar Series. Stanford, CA, US.
2024. Engineering in vivo chimeric antigen receptor macrophages (CARMs) using mRNA-exosomes for cancer immunotherapy. Invited. 2024 NCI Alliance for Nanotechnology in Cancer Principal Investigator Meeting. Rockville, MD, US.
2023. Intradermally delivered mRNA encapsulating extracellular vesicles for collagen-replacement therapy. Conference. MD Anderson Research Townhall. Houston, US.
2023. Engineering approaches to cancer Therapy., Cancer Biology Seminar Series. Conference. Department of Cancer Biology. Houston, US.
2021. Targeting Phagocytosis for GBM Immunotherapy. Invited. American Brain Tumor Association, US.
2020. Improving immune-vascular crosstalk for cancer immunotherapy,. Invited. AACR Annual Meeting, Virtual, US.
2017. Selective macrophage evading nanomedicine enables enhanced delivery and therapeutic efficacy of anti-cancer agents against solid tumors. Invited. Gordon Research Conference. Mount Snow, VT, US.
2017. Chemoradiation Combined with Phosphatidylserine-Targeting Antibody Enhances Systemic Antitumor immune Responses. Conference. ASTRO Annual Meeting. San Diego, CA, US.
2016. Circulating Lymphocyte Count During Neoadjuvant Chemoradiation Therapy for Esophageal Cancer as a Predictive Biomarker of Pathologic Complete Response. Conference. ASTRO Annual Meeting. Boston, MA, US.
2016. CD4:CD8 Ratio in Mycosis Fungoides: Prognostic and Predictive Value of Circulating T lymphocyte Subsets for Outcomes after Total Skin Electron Beam Radiation. Conference. ASTRO Annual Meeting. Boston, MA, US.
2015. Circulating myeloid precursor profile as potential marker to differentiate radiation changes from tumor recurrence after brain stereotactic radiosurgery. Conference. AACR Annual Meeting. Philadelphia, PA, US.
2015. Temporally-Dependent Intracranial Control of Melanoma Brain Metastasis by Stereotactic Radiation Therapy in Patients Treated With Immune Checkpoint Blockade. Conference. ASTRO Annual Meeting. San Antonio, TX, US.
2015. Microenvironmental modulation improves nanomedicine delivery into brain tumors. Conference. SNO Annual Scientific Meeting. San Antonio, TX, US.

International Presentations

2025. Skeletal muscle–targeted non-viral delivery of full-length dystrophin mRNA for Duchenne muscular dystrophy. Conference. CRS Singapore 2025. Singapore, SG.
2024. Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics. Conference. Controlled Release Society Annual Meeting & Expo. Bologna, IT.
2023. Cancer Immunotherapy based on Image-Guided STING Activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Invited. International Soceity for Therapeutic Ultrasound (ISTU), US.
2022. Microbubble-assisted Ultrasound Sound-guided Immunotherapy of Cancer (MUSIC). Invited. Controlled Release Society (CRS) Annual Meeting. Montreal, CA.
2015. Temporally dependent intracranial control of melanoma brain metastasis by stereotactic radiotherapy in patients treated with immune-checkpoint blockade. Conference. Gilbert H. Fletcher Society Annual Meeting. Hunan, CN.

Formal Peers

2022. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Invited. International Society for Therapeutic Ultrasound (ISTU) Rising Scientist Webinar, US.
2021. Targeting Innate Immune System for Cancer Therapy. Invited. Houston Methodist Research Institute. Houston, TX, US.
2020. Phagocytosis checkpoints as new cancer immunotherapy. Invited. Houston Methodist Research Institute, US.
2018. Therapeutic targeting of tumor microenvironment for cancer immunotherapy. Invited. University of Southern California, US.
2018. Targeting the tumor microenvironment for cancer therapy,. Invited. University of Toronto, US.
2018. Tumor microenvironment as new target for cancer therapy. Invited. University of Florida, US.
2018. Targeting the tumor microenvironment for cancer immunotherapy. Invited. UC San Diego, US.
2017. Tumor microenvironment as a new target for cancer therapy. Invited. University of Michigan, US.
2017. Targeting the tumor microenvironment for cancer therapy. Invited. Ohio State University, US.

Less

Grant & Contract Support

Date:	2025 - 2028
Title:	Ultrasound-Guided Neoadjuvant Activation of Innate Immunity in Metastatic Melanoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP260192

Date:	2025 - 2030
Title:	Therapeutic benefit of vascular progenitor cells and exosome therapy in heart failur
Funding Source:	NIH
Role:	PI
ID:	PA-25-301

Date:	2025 - 2030
Title:	Microbial-inspired immune-stimulating antibody-toxin conjugate for cancer immunotherapy
Funding Source:	NCI
Role:	Co-PI
ID:	1R01CA305986-01

Date:	2025 - 2028
Title:	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP230307

Date:	2024 - 2026
Title:	Engineering a Targeted, Acoustically Responsive Image-Guided GBM Immunotherapy
Funding Source:	American Brain Tumor Association
Role:	PI
ID:	ARC2400008

Date:	2024 - 2026
Title:	Engineering in vivo chimeric antigen receptor macrophages for diffuse midline glioma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP240493

Date:	2024 - 2029
Title:	Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA291876

Date:	2024 - 2028
Title:	Ultrasound-mediated activation of STING using a clinical scanner for the immunotherapy of cancer
Funding Source:	American Cancer Society
Role:	PI
ID:	RSG23-1155943-01

Date:	2023 - 2027
Title:	Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	1R01CA284108-01

Date:	2022 - 2024
Title:	Reversing Aging Associated Resistance to Cancer Immunotherapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP220553

Date:	2022 - 2026
Title:	Glioblastoma immunotherapy with dual phagocytosis checkpoint blockade
Funding Source:	American Cancer Society (ACS)
Role:	PI
ID:	2021ACS000RSG0000218113

Date:	2022 - 2025
Title:	A Novel Selective IL-2 Mimic for Combination Immunotherapy of Breast Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI
ID:	RP220357

Date:	2022 - 2023
Title:	Renal Cell Carcinoma Surveillance by Immuno-Lipoplex Nanoparticle Platform
Funding Source:	NIH/NCI
Role:	PI
ID:	1R21 CA252344

Date:	2022 - 2022
Title:	Eliciting abscopal effect of combined radiotherapy, PD-1 blockade and NL-201 in localized and metastatic cancers
Funding Source:	Neoleukin Inc
Role:	PI
ID:	LS2022-00060546-JW

Date:	2021 - 2022
Title:	Engaging the Immune System to Improve Metastatic Breast Cancer Treatment
Funding Source:	Susan G. Komen Foundation
Role:	PI
ID:	CCR19605871

Date:	2021 - 2026
Title:	6-thio-deoxyguanosine: A Novel Immunogenic Telomerase-mediated Therapy in Glioblastoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	U19CA264385

Date:	2021 - 2024
Title:	Treating Metastatic Cancer using Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer (MUSIC)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP210199

Date:	2021 - 2023
Title:	Circulating Exosome-Based Biomarker for Treatment Monitoring in Anal Cancer
Funding Source:	Radiation Oncology Institute
Role:	PI
ID:	ROI2021-9131

Date:	2021 - 2025
Title:	Ultrasound-Guided Targeted STING Activation for Breast Cancer Immunotherapy
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	W81XWH21-1-0332

Date:	2021 - 2026
Title:	Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody
Funding Source:	NIH/NINDS
Role:	PI
ID:	R01NS117828

Date:	2021 - 2023
Title:	A Phagocytosis Modulating Nanomedicine for Targeted Breast Cancer Immunotherapy
Funding Source:	NIH/NCI
Role:	PI
ID:	5K08CA241070-02

Date:	2019 - 2021
Title:	CD24 as a novel therapeutic target for glioblastoma immunotherapy
Funding Source:	UT Southwestern Simmons Cancer Center
Role:	PI

Date:	2019 - 2021
Title:	Bridging Innate and Adaptive Glioblastoma Immunity via Phagocytosis Checkpoint Blockade
Funding Source:	American Brain Tumor Association
Role:	PI
ID:	DG1900021

Date:	2018 - 2023
Title:	First time, tenure track faculty recruitment award
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RR180017

Date:	2018 - 2019
Title:	UT Rising Stars Award
Funding Source:	University of Texas Systems
Role:	PI

Date:	2017 - 2018
Title:	High throughput multiplexed immunological profiling of glioblastoma
Funding Source:	ASCO/Conquer Cancer Foundation
Role:	PI

Date:	2016 - 2017
Title:	Combining chemoradiation with anti-phosphatidylserine blockade promotes immunogenic phagocytosis to generate long-lasting anti-tumor immunity
Funding Source:	Radiological Society of North America (RSNA)
Role:	PI

CV information above last modified April 30, 2025

Wen Jiang, MD, PhD

About Dr. Wen Jiang

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Wen Jiang, MD, PhD

About Dr. Wen Jiang

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer